{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+Urothelial+Cancer&page=5", "query": { "condition": "Locally Advanced Urothelial Cancer", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 128, "total_pages": 13, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+Urothelial+Cancer&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+Urothelial+Cancer&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-06T14:20:56.102Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07419295", "title": "A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "Sacituzumab tirumotecan", "type": "BIOLOGICAL" }, { "name": "Vinflunine", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Rescue medications for sacituzumab tirumotecan", "type": "DRUG" }, { "name": "Rescue medications for chemotherapy", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 590, "start_date": "2026-04-23", "completion_date": "2030-04-23", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-06T14:20:56.102Z", "location_count": 16, "location_summary": "Washington D.C., District of Columbia • Atlanta, Georgia • Baltimore, Maryland + 13 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Traverse City", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT07419295" }, { "nct_id": "NCT05645692", "title": "A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urothelial Cancer" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Tobemstomig", "type": "DRUG" }, { "name": "Tiragolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 204, "start_date": "2023-04-13", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-10-06T14:20:56.102Z", "location_count": 2, "location_summary": "Cleveland, Ohio • Houston, Texas", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05645692" }, { "nct_id": "NCT03473756", "title": "Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Urothelial Carcinoma" ], "interventions": [ { "name": "Rogaratinib (BAY1163877)", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2018-05-15", "completion_date": "2024-07-10", "has_results": true, "last_update_posted_date": "2025-04-09", "last_synced_at": "2026-10-06T14:20:56.102Z", "location_count": 4, "location_summary": "Tucson, Arizona • Chicago, Illinois • Detroit, Michigan + 1 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03473756" }, { "nct_id": "NCT04887831", "title": "Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urothelial Carcinoma", "Bladder Cancer", "Myelosuppression Adult", "Chemotherapy-induced Neutropenia", "Metastatic Bladder Cancer" ], "interventions": [ { "name": "Trilaciclib", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Avelumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "G1 Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 92, "start_date": "2021-06-04", "completion_date": "2024-03-01", "has_results": true, "last_update_posted_date": "2025-09-08", "last_synced_at": "2026-10-06T14:20:56.102Z", "location_count": 13, "location_summary": "Los Angeles, California • Whittier, California • Littleton, Colorado + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Littleton", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Pensacola", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04887831" }, { "nct_id": "NCT05923190", "title": "Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urothelial Carcinoma", "Metastatic Urothelial Carcinoma", "Locally Advanced Urothelial Carcinoma" ], "interventions": [ { "name": "Enfortumab vedotin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2023-06-14", "completion_date": "2029-07-01", "has_results": false, "last_update_posted_date": "2026-03-19", "last_synced_at": "2026-10-06T14:20:56.102Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05923190" }, { "nct_id": "NCT03785925", "title": "A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urinary Bladder Neoplasm", "Neoplasm Metastasis" ], "interventions": [ { "name": "Bempegaldesleukin", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Nektar Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 192, "start_date": "2019-04-29", "completion_date": "2022-06-30", "has_results": true, "last_update_posted_date": "2023-03-28", "last_synced_at": "2026-10-06T14:20:56.102Z", "location_count": 8, "location_summary": "San Francisco, California • Whittier, California • Aurora, Colorado + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Newnan", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03785925" }, { "nct_id": "NCT01023958", "title": "Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "BI 6727, IV infusion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2009-11-19", "completion_date": "2011-09-19", "has_results": true, "last_update_posted_date": "2017-11-22", "last_synced_at": "2026-10-06T14:20:56.102Z", "location_count": 19, "location_summary": "Beverly Hills, California • Los Angeles, California • Miami, Florida + 14 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01023958" }, { "nct_id": "NCT02925533", "title": "Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "B-701", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mark Pomerantz, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "18 Years to 18 Years" }, "enrollment_count": 1, "start_date": "2016-12-14", "completion_date": "2017-06", "has_results": false, "last_update_posted_date": "2017-06-27", "last_synced_at": "2026-10-06T14:20:56.102Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02925533" }, { "nct_id": "NCT03679767", "title": "A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Non-small Cell Lung Cancer", "Locally Advanced Urothelial Cancer", "Metastatic Urothelial Cancer", "Unresectable Melanoma", "Metastatic Melanoma", "Locally Advanced Renal Cell Carcinoma", "Metastatic Clear-Cell Renal Cell Carcinoma" ], "interventions": [ { "name": "Retifanlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 121, "start_date": "2019-01-09", "completion_date": "2022-06-28", "has_results": true, "last_update_posted_date": "2023-07-21", "last_synced_at": "2026-10-06T14:20:56.102Z", "location_count": 18, "location_summary": "Fresno, California • San Marcos, California • Santa Rosa, California + 13 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "San Marcos", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Santa Rosa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03679767" }, { "nct_id": "NCT04223856", "title": "Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Urothelial Cancer" ], "interventions": [ { "name": "Enfortumab vedotin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 886, "start_date": "2020-03-30", "completion_date": "2028-03-01", "has_results": true, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-10-06T14:20:56.102Z", "location_count": 34, "location_summary": "Chandler, Arizona • Tucson, Arizona • Burbank, California + 28 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04223856" } ] }